Cardiovascular Clinical Studies

This channel includes news and new technology innovations from cardiovascular clinical trials. These clinical studies include all cardiac subspecialties.

When added to standard blood pressure medication, new drug could minimize the need for pills and reduce cardiovascular risks

News | Cardiovascular Clinical Studies

One Injection of Novel Drug Cuts Systolic Blood Pressure by Up to 12 mmHg

April 7. 2024 — A single subcutaneous injection of the investigational drug zilebesiran, when added to existing ...

April 07, 2024

Results show drug is effective and safe, leaves open question of optimal dosing

News | Cardiovascular Clinical Studies

Study Finds Olezarsen Cuts Triglyceride Levels by About Half

April 7, 2024 — An estimated 1 in 5 U.S. adults—and more than 2 in 5 adults aged 60 years and older—have elevated ...

April 07, 2024

90% of high-risk patients on lerodalcibep achieved guideline-recommended cholesterol targets

News | Cardiovascular Clinical Studies

Novel PCSK9 Inhibitor Cut LDL Cholesterol Levels by More Than Half

April 7, 2024 — Among patients at high or very high risk for a heart attack or stroke, the addition of the ...

April 07, 2024

Novel drug shows promise for treating severe hypertriglyceridemia in patients at high risk for pancreatitis

News | Cardiovascular Clinical Studies

Plozasiran Reduces Triglyceride Levels by 74% at 24 Weeks

April 7, 2024 — In patients with severely elevated triglyceride levels at risk for developing acute pancreatitis, the ...

April 07, 2024

$Study shows no benefit for heart failure overall but suggests different effects in those with preserved versus reduced ejection fraction$

News | Cardiovascular Clinical Studies

RELIEVE-HF Trial Outcomes Reported at ACC.24 Find Impact of Interatrial Shunt May Vary by Heart Failure Type

April 6, 2024 — Patients with heart failure who had a small shunt inserted between the heart’s left and right atria did ...

April 06, 2024

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack

News | Cardiovascular Clinical Studies

EMPACT-MI Trial Outcomes Reported at ACC.24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

April 6, 2024 — Use of the sodium glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin following a heart attack did ...

April 06, 2024

Exploratory analysis finds beneficial effect on patient outcomes at one year, according to a study presented at ACC.24.

News | Cardiovascular Clinical Studies

Research Presented at ACC 2024 Found No Reduction in 90-Day Deaths, Heart Attacks With Human Apo/A1

April 6, 2024 — The first trial of a novel strategy for removing cholesterol from patients’ arteries did not reduce the ...

April 06, 2024

The Minneapolis Heart Institute Foundation (MHIF) is presenting data on trends in ST-elevation myocardial infarction (STEMI) at the American College of Cardiology’s Annual Scientific Session (ACC.24). An analysis of nearly 8,000 STEMI patients over 20 years found the majority of STEMI occur in individuals without prior cardiovascular disease.

News | ACC

Research Data from Minneapolis Heart Institute Foundation at ACC 2024 Reveal Trends in Cardiovascular Risk Factors and Preventive Medication Use Prior to Heart Attacks

April 6, 2024 — The Minneapolis Heart Institute Foundation (MHIF) is presenting leading research focused on trends ...

April 06, 2024

Registration is open for a leading conference on structural heart disease announced by the Cardiovascular Research Foundation, CRF.

News | Cardiovascular Business

Cardiovascular Research Foundation, CRF, Introduces New York Valves: The Structural Heart Summit

April 5, 2024 — The Cardiovascular Research Foundation (CRF) has announced New York Valves: The Structural Heart Summit ...

April 05, 2024

Cardiawave SA will present the 30-day follow-up results for 60 patients enrolled in its European pivotal study to the 73rd annual conference of the American College of Cardiology in Atlanta, Georgia

News | Cardiovascular Ultrasound

Cardiawave is Presenting the 30-day Follow-up Results from its “Valvosoft Pivotal Study” on the Teatment of Severe Symptomatic Aortic Valve Stenosis at ACC24

April 5, 2024 — Cardiawave SA, a French medtech company that has developed an innovative Non-Invasive focused Ultrasound ...

April 05, 2024

Early coronary disease and impaired heart function, with increased coronary vessel wall thickness, in asymptomatic, middle-aged individuals living with HIV has been reported in a new study published today in Radiology: Cardiothoracic Imaging, a journal of the Radiological Society of North America (RSNA).

News | Population Health

New Study Finds Early Coronary Disease, Impaired Heart Function in Asymptomatic People with HIV

April 4, 2024 — A new study found increased coronary vessel wall thickness that was significantly associated with ...

April 04, 2024

Study shows women quickly catch up to men in terms of cardiovascular risk

News | Womens Cardiovascular Health

Heart Health Declines Rapidly After Menopause

April 2, 2024 — A woman’s cardiovascular risk can rise sharply after she goes through menopause, quickly catching up to ...

April 02, 2024

Study finds patients on average consume more than twice the recommended daily amount of sodium with little variation across socioeconomic groups

News | Womens Cardiovascular Health

Majority of People with Heart Disease Consume Too Much Sodium

April 2, 2024 — Individuals with heart disease stand to gain the most from a low sodium diet but, on average, consume ...

April 02, 2024

Large study adds to growing body of evidence that vaping may harm the heart

News | Heart Failure

Study Links E-Cigarette Use with Higher Risk of Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

April 02, 2024

News | FDA

U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

April 1, 2024 — Esperion announced that the United States Food and Drug Administration (FDA) has approved broad new ...

April 01, 2024